TauRx global phase 3 trial in Alzheimer's disease with tau aggregation inhibitor LMTX

Research output: Contribution to journalAbstractpeer-review


There have been 19 phase2/3 clinical trial failures in 15,000 AD subjects to date, all aiming to reduce amyloid pathology. The tau theory has offered an entirely viable alternative conceptual framework, largely ignored for the last 20 years. The filaments of the Alzheimer neurofibrillary tangle are made of a truncated fragment from the repeat domain of tau. This truncated fragment can catalyse the conversion of normal soluble tau into aggregated oligomeric and fibrillary forms which, in turn, can infect neighbouring neurons.
Original languageEnglish
Pages (from-to)S26
Number of pages1
JournalNeurobiology of Aging
Issue numberSuppl. 1
Early online date14 Mar 2014
Publication statusPublished - Mar 2014
Event13th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy - Geneva, Switzerland
Duration: 26 Mar 201429 Mar 2014


  • tau
  • methylthioninium
  • Alzheimer's disease

Cite this